|
|
||||||||
From the Peripheral Neuropathy Research Laboratory (Dr. Dyck, Ms. Karnes, and Ms. Gillen), the Section of Biostatistics (Dr. O'Brien), and the Section of Engineering Development (Mr. Zimmerman and Mr. Johnson), Mayo Clinic and Mayo Foundation, Rochester, MN.
Estimates of vibratory detection threshold may be used to detect, characterize, and follow the course of sensory abnormality in neurologic disease. The approach is especially useful in epidemiologic and controlled clinical trials. We studied which algorithm of testing and finding threshold should be used in automatic systems by comparing among algorithms and stimulus conditions for the index finger of healthy subjects and for the great toe of patients with mild neuropathy. Appearance thresholds obtained by linear ramps increasing at a rate less than 4.15 µm/sec provided accurate and repeatable thresholds compared with thresholds obtained by forced-choice testing. These rates would be acceptable if only sensitive sites were studied, but they were too slow for use in automatic testing of insensitive parts. Appearance thresholds obtained by fast linear rates (4.15 or 16.6 µm/sec) overestimated threshold, especially for sensitive parts. Use of the mean of appearance and disappearance thresholds, with the stimulus increasing exponentially at rates of 0.5 or 1.0 just noticeable difference (JND) units per second, and interspersion of null stimuli, Békésy with null stimuli, provided accurate, repeatable, and fast estimates of threshold for sensitive parts. Despite the good performance of Békésy testing, we prefer forced choice for evaluation of the sensation of patients with neuropathy.
Address correspondence and reprint requests to Dr. P.J. Dyck, Mayo Clinic and Mayo Foundation, Rochester, MN 55905.
Received January 9, 1990. Accepted for publication in final form March 19, 1990.
This article has been cited by other articles:
![]() |
M. J. Hilz, M. Brys, H. Marthol, B. Stemper, and M. Dutsch Enzyme replacement therapy improves function of C-, A{delta}-, and A{beta}-nerve fibers in Fabry neuropathy Neurology, April 13, 2004; 62(7): 1066 - 1072. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.E. Shy, E.M. Frohman, Y.T. So, J.C. Arezzo, D.R. Cornblath, M.J. Giuliani, J.C. Kincaid, J.L. Ochoa, G.J. Parry, and L.H. Weimer Quantitative sensory testing: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, March 25, 2003; 60(6): 898 - 904. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Simovic, J. M. Isner, A. H. Ropper, A. Pieczek, and D. H. Weinberg Improvement in Chronic Ischemic Neuropathy After Intramuscular phVEGF165 Gene Transfer in Patients With Critical Limb Ischemia Arch Neurol, May 1, 2001; 58(5): 761 - 768. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |